drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Anti-CD38 IgG1 monoclonal antibody that induces myeloma cell death via ADCC, CDC, and ADCP; can trigger direct apoptosis, inhibit CD38 ectoenzyme/adenosine signaling, and deplete CD38+ immunosuppressive cells.
nci_thesaurus_concept_id
C90578
nci_thesaurus_preferred_term
Isatuximab
nci_thesaurus_definition
A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
drug_mesh_term
Isatuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Isatuximab is an anti‑CD38 IgG1 monoclonal antibody that binds CD38 on malignant plasma cells, inducing cell death via antibody‑dependent cellular cytotoxicity (ADCC), complement‑dependent cytotoxicity (CDC), antibody‑dependent cellular phagocytosis (ADCP), and direct apoptosis. It also inhibits CD38 ectoenzyme/adenosine signaling and depletes CD38‑positive immunosuppressive cells, enhancing anti‑tumor immunity.
drug_name
Isatuximab
nct_id_drug_ref
NCT05690984